Should health technology assessment be more patient centric? If so, how?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Women's priorities towards ovarian cancer testing: a best-worst scaling study.BMJ open · 2022
   Pooled it
2. Valuation of EQ-5D-5L health states from cancer patients' perspective: a feasibility study.The European journal of health economics : HEPAC : health economics in prevention and care · 2024
   Article
3. A situational and stakeholder analysis of health technology assessment in Zimbabwe.International journal of technology assessment in health care · 2024
   Article
4. Systematic review for the development of a core outcome set for monofocal intraocular lenses for cataract surgery.Frontiers in medicine · 2024
   Article
5. Embedding the Patient-Citizen Perspective into an Operational Framework for the Development and the Introduction of New Technologies in Rehabilitation Care: The Smart&Touch-ID Model.Healthcare (Basel, Switzerland) · 2023
   Article
6. The societal impact of implementing an at-home blood sampling device for chronic care patients: patient preferences and cost impact.BMC health services research · 2022
   Article
7. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.The European journal of health economics : HEPAC : health economics in prevention and care · 2022
   Article
8. How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries.Frontiers in pharmacology · 2022
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as